United Therapeutics (UTHR) Hits New 52-Week Low at $88.25

Shares of United Therapeutics Co. (NASDAQ:UTHR) reached a new 52-week low on Wednesday . The company traded as low as $88.25 and last traded at $89.74, with a volume of 24375 shares traded. The stock had previously closed at $90.50.

UTHR has been the topic of a number of recent analyst reports. TheStreet upgraded United Therapeutics from a “c+” rating to a “b-” rating in a research note on Monday, February 11th. Wedbush set a $273.00 target price on United Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 8th. BidaskClub downgraded United Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Barclays dropped their price target on United Therapeutics from $100.00 to $95.00 and set an “underweight” rating on the stock in a research report on Friday, March 1st. Finally, Oppenheimer set a $160.00 price target on United Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. United Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $129.00.

The stock has a market cap of $3.91 billion, a price-to-earnings ratio of 6.77 and a beta of 1.01. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45.



United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($13.96). United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The company had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. During the same period in the previous year, the business earned $3.76 EPS. United Therapeutics’s revenue for the quarter was down 6.8% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Co. will post -5.03 earnings per share for the current fiscal year.

In related news, Director Christopher Patusky sold 3,370 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $110.75, for a total transaction of $373,227.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 8.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC boosted its holdings in United Therapeutics by 62.5% in the first quarter. Jane Street Group LLC now owns 5,699 shares of the biotechnology company’s stock worth $669,000 after acquiring an additional 2,193 shares in the last quarter. Sio Capital Management LLC boosted its holdings in United Therapeutics by 12.2% in the first quarter. Sio Capital Management LLC now owns 33,655 shares of the biotechnology company’s stock worth $3,950,000 after acquiring an additional 3,655 shares in the last quarter. Blackstone Group L.P. acquired a new stake in United Therapeutics in the first quarter worth about $6,551,000. Ladenburg Thalmann Financial Services Inc. boosted its holdings in United Therapeutics by 21.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,025 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 182 shares in the last quarter. Finally, Coastal Investment Advisors Inc. acquired a new stake in United Therapeutics in the first quarter worth about $88,000. 97.29% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “United Therapeutics (UTHR) Hits New 52-Week Low at $88.25” was reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://dakotafinancialnews.com/2019/05/18/united-therapeutics-uthr-hits-new-52-week-low-at-88-25.html.

United Therapeutics Company Profile (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What are retained earnings?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.